Formycon: Frische Mittel von neuem strategischen Investor eingeworben; KAUFEN

Last week Formycon presented at the AlsterResearch Health Care Conference, for which a recording can be watched at https://research-hub.de/events. Yesterday evening, Formycon announced the raising of EUR 82.84m in fresh funds from Gedeon Richter Plc, a Budapest-based company active in pharmaceutical manufacturing, research and development, sales and marketing. Richter will hold around 9% of Formycon. The proceeds will be used for further development of the biosimilar pipeline, including the start of a further biosimilar candidate, FYB210, in H2 2024. AlsterResearch sees the increased willingness to make strategic investments as evidence of Formycon's operational progress and the successful implementation of its strategy to date. AlsterResearch’s analysts include the capital increase in their model and adjust the price target to EUR 91.00 (old: EUR 100.00) as a result of the higher number of shares. AlsterResearch confirms the BUY rating.

Analyse ist abrufbar unter ResearchHUB .

https://www.research-hub.de/disclaimer

Die Formycon Aktie wird zum Zeitpunkt der Veröffentlichung der Nachricht mit einem Plus von +1,77 % und einem Kurs von 51,70EUR auf Tradegate (30. Januar 2024, 12:13 Uhr) gehandelt.